PINPOINT Trademark

Trademark Overview


On Tuesday, April 28, 2020, a trademark application was filed for PINPOINT with the United States Patent and Trademark Office. The USPTO has given the PINPOINT trademark a serial number of 88891086. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Wednesday, March 6, 2024. This trademark is owned by Dragonfly Therapeutics, Inc.. The PINPOINT trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Services in the field of computer assisted research in the nature of pharmaceutical research in the field of research and development of therapeutic biomolecules, namely, bioinformatics services directed to immune-engaging therapeutic biomolecule research and development; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely services to analyze immunotherapy treatments, including treatment of cancer, autoimmune disease, infectious disease, fibrotic disease, or cellular senescence; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely, services using comparative analysis across diseased and healthy tissue, between patients, between...
pinpoint

General Information


Serial Number88891086
Word MarkPINPOINT
Filing DateTuesday, April 28, 2020
Status732 - THIRD EXTENSION - GRANTED
Status DateWednesday, March 6, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements


Goods and ServicesServices in the field of computer assisted research in the nature of pharmaceutical research in the field of research and development of therapeutic biomolecules, namely, bioinformatics services directed to immune-engaging therapeutic biomolecule research and development; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely services to analyze immunotherapy treatments, including treatment of cancer, autoimmune disease, infectious disease, fibrotic disease, or cellular senescence; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely, services using comparative analysis across diseased and healthy tissue, between patients, between cells, comparing protein expression and surface localization information, and analysis of preclinical and clinical data from therapeutic biomolecules, to identify targets for immunotherapy development; all of the foregoing excluding providing temporary use of non-downloadable computer software for data mining, data query, and data analysis excluding providing temporary use of non-downloadable computer software for applying statistical, econometric, and machine learning methods to data sets to generate data transformations and analyses and for displaying, visualizing, and interpreting the results of these data transformations and analyses; excluding providing temporary use of non-downloadable computer software, namely, educational software featuring instruction, testing, and assessment in the fields of statistics, econometrics, and machine learning for secondary, postsecondary and skills education; excluding biological preparations biological preparations in the nature of eukaryotic cells, isogenic cell lines and bio-production cell lines generated using base editing engineering for scientific, laboratory or medical research; excluding reagents, plasmids and assays for scientific, genetic and medical research; excluding genomic reference control samples for medical laboratory use; excluding molecular biology research tools, in the nature of chemical, biological and biochemical reagents; excluding biological preparations in the nature of separate base editing components including mRNA, rRNA, gRNA, deaminase, nickase, ribonucleotide protein (RNP) for use in scientific, laboratory or medical research; excluding biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; excluding biological and chemical reagents including complexes of these molecules for research and for clinical and industrial use; excluding diagnostic preparations and materials generated by the use of base editing components for medical purposes; excluding chemical preparation for use in DNA analysis for medical purposes; excluding biological preparations in the nature of DNA, RNA and parts thereof for medical purposes; excluding biological preparations in the nature of DNA extracts for medical purposes; excluding biological preparations in the nature of gene editing enzymes for medical purposes; excluding biological preparations in the nature of protein cell lysates, genomic DNA preparations and Formalin Fixed, Paraffin Embedded (FFPE) engineered tumour tissue mimics for medical diagnostic use; excluding biological preparations in the nature of biological, biochemical and chemical reagents, including living cells, genetically modified cells and vectors, genomic DNA, cell cultures and mutant and normal isogenic cell line pairs, peptides, proteins and nucleic acids or complexes of these molecules for medical use; excluding collections of DNA and gene sequences for research and reference purposes provided as DNA microarrays and DNA chips; excluding treatment of biopharmaceutical materials; excluding custom manufacture of cells and vectors for diagnostic, medical and commercial applications in relation to cell and gene therapies; excluding custom cell-line engineering services; excluding gene base-editing services for research purposes; excluding gene engineering services; excluding research and development services in the creation of databases or collections of information on biologicals including cells and cell lines for research purposes; excluding creating and providing databases or collections of information on normal and mutated genes for research purposes; excluding providing DNA reference standards for research purposes; excluding providing DNA reference databases being collections of DNA and gene sequences for research purposes; excluding research on cell line models; excluding contract research on cell line models; excluding research and development services relating to targeting therapies to individuals; excluding establishing patient genotypes for research or analysis purposes; excluding research and development services relating to combining therapies for individuals; excluding research and development relating to reagents; excluding disease modelling for research purposes; excluding design of clinical trials for research purposes; excluding research and development in re-positioning existing drugs from other therapeutic indications; excluding services relating to biological and medical research and research and development in the field of cells and cell therapies, genome editing, genetic engineering and gene therapies

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, May 8, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDragonfly Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Party NameDragonfly Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events


Event DateEvent Description
Thursday, March 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 6, 2024SOU EXTENSION 3 GRANTED
Wednesday, March 6, 2024SOU EXTENSION 3 FILED
Wednesday, March 6, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, September 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 11, 2023SOU EXTENSION 2 GRANTED
Monday, September 11, 2023SOU EXTENSION 2 FILED
Monday, September 11, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 20, 2023SOU EXTENSION 1 GRANTED
Monday, February 20, 2023SOU EXTENSION 1 FILED
Monday, February 20, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 16, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 27, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 23, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 23, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 23, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 23, 2021NON-FINAL ACTION E-MAILED
Tuesday, November 23, 2021NON-FINAL ACTION WRITTEN
Wednesday, October 27, 2021SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, August 23, 2021ASSIGNED TO EXAMINER
Monday, April 19, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, April 19, 2021LETTER OF SUSPENSION E-MAILED
Monday, April 19, 2021SUSPENSION LETTER WRITTEN
Tuesday, February 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 8, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 7, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, August 7, 2020NON-FINAL ACTION E-MAILED
Friday, August 7, 2020NON-FINAL ACTION WRITTEN
Wednesday, July 22, 2020ASSIGNED TO EXAMINER
Friday, May 8, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 1, 2020NEW APPLICATION ENTERED